27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
As COVID-related restrictions begin to ease across the globe, some industries are feeling the benefits more than others. When it comes to Canadian recreational cannabis sales, new Hifyre scanner data reveals a 10% improvement sequentially, noted Cantor Fitzgerald’s Pablo Zuanic in his latest industry report.
The analyst was projecting more of an accelerated growth rate compared to the second-quarter growth pace, but that didn’t happen despite cannabis shops now receiving in-store traffic.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Hifyre estimated August sales reached CA$347 million ($275.6 million), representing
2% month-over-month growth, after hitting CA$339 million in July (which was up 7% from June). The average monthly sales for both months amount to CA$343 million, which is 10% higher than the second quarter monthly average, explained Zuanic.
“If we assumed September is flat month-over-month, this would still imply about 11% sequential quarter-over-quarter growth,” the analyst detailed, adding that this is neither good nor bad, just not “accelerated” as he was expecting.
The report also revealed that pre-rolls have driven growth accounting for 24% of sales, improving 27% over the second quarter monthly average. Flower sales were up only 2%, accounting for almost half of the sales, while vapes (13% of sales) and edibles (5% of sales) jumped 9% and 20%, respectively. Concentrates sales improved 24% and accounted for 4% of industry sales.
Performance By Company
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Industry giants had various performances, with Organigram (NASDAQ: OGI) and Auxly
(OTCQX: CBWTF) standing out and outperforming with 30% and 22%, respectively, Zuanic highlighted.
- Cronos Group (NASDAQ: CRON) – Up 50%
- Organigram – Up 30%;
- Auxly – Up 22%;
- Tilray (NASDAQ: TLRY) – Up 6%;
- HEXO (NASDAQ: HEXO) – Up 7%;
- Village Farms Intl (NASDAQ: VFF) – Up 7%;
- Canopy Growth (NASDAQ: CGC) – Down 12% ;
- Aurora Cannabis (NASDA: ACB) – Down 16%;
- Sundial Growers ( NASDAQ: SNDL) – Down 4%.
“In terms of companies reporting July or August quarters, we calculate Organigram is on pace for a significant beat with August quarter sales up 44% sequentially, while HEXO (July quarter) and Tilray (August) point to low single-digit pro forma growth,” noted Zuanic.
Market Share By Company
- Tilray – 15.3% share (consisting of Aphria’s 11.1% and Tilray’s 4.2%);
- HEXO (including Hexo and recently acquired Redecan, Zenabis and 48North) - 12.7% share;
- Canopy Growth (counting Supreme) – 10.2% share;
- Organigram – 7.1% share;
- Village Farms Intl – 7.0% share;
- Auxly – 5.3% share;
- Cronos Group – 4.2% share;
- Aurora Cannabis – 3.9% share;
- Sundial Growers – 1.9% share.
Price Action
Organigram’s shares were trading 0.75% lower at $2.63 per share during Tuesday's pre-market session.
Photo: Courtesy of Visual Stories || Micheile on Unsplash
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.